As he begins his tenure at Fox Chase Cancer Center, Dr. Robert Winn brings a national reputation in cancer leadership, discovery, and equitable access - and a vision for science that reaches farther than the clinic.
When Robert A. Winn, MD, talks about cancer science, he often begins with opportunity, not as a personal anecdote alone, but as a principle that has shaped his career as a physician-scientist, cancer center leader, and advocate for broader access to discovery.
That perspective has shaped a career that spans pulmonary medicine, lung cancer biology, cancer center leadership, national policy, improving access to clinical trial enrollment, and community-engaged research. It also helps explain why Dr. Winn sees his new role at Fox Chase not simply as a leadership appointment, but as a privilege: the opportunity to build on one of the nation’s most storied cancer centers at a moment when oncology is being challenged to think more expansively about discovery, access, trust, and impact.
Fox Chase has long occupied a distinct place in cancer science. Its legacy includes discoveries that helped shape the modern genetic understanding of cancer, including the 1959 discovery of the Philadelphia chromosome, which helped lay the groundwork for the era of precision medicine. That scientific foundation has continued to inform clinical practice, from Fox Chase’s role as a founding member of the National Comprehensive Cancer Network to its standing as one of the nation’s first NCI-designated comprehensive cancer centers.
For Dr. Winn, that history was central to the draw, not as a legacy to preserve unchanged, but as a foundation to extend. When asked what brought him to Fox Chase at this point in his career, his answer was simple: “It’s Fox Chase.”
His answer was more than shorthand for institutional reputation. For Dr. Winn, Fox Chase represents a rare combination: deep scientific credibility, clinical excellence, a culture of connection, and a catchment area where the work has urgent meaning. He was struck by what he describes as “amazing scientists, amazing researchers, amazing clinicians,” and by a sense of teamwork and belonging that can be easy for those inside an institution to overlook.
His goal is not to replace that foundation. It is to build from it
Dr. Winn’s vision is rooted in what he calls “From Bench to Bedside to the Block,”- an extension of the traditional bench-to-bedside paradigm that brings the same rigor to community outreach efforts with a fundamental set of questions: What can communities teach researchers about risk, biology, behavior, access, trust, and outcomes? How can data from real-world populations help refine scientific questions? How can the next generation of cancer discovery move not only from the bench to the bedside, but beyond the bedside and into the places where people live?
He describes this as the “omics of the community,” a complement to genomics, proteomics, and other molecular tools. In his view, the future of cancer science will require a more sophisticated understanding of the relationship between biology and lived environment, what he calls a “social molecular framework.”
That framework is especially relevant in Philadelphia, where world-class scientific institutions exist alongside communities that continue to experience disproportionate barriers to prevention, screening, clinical trials, and timely care. Dr. Winn sees Temple Health’s Fox Chase Cancer Center as uniquely positioned to address that challenge, not through outreach as an afterthought, but through science that is informed by community from the start.
“The science can’t stop at the bedside,” he said. “If you’re really going to talk about major impact and reductions, it has to get beyond just the bedside.”
That is a provocative leadership proposition. It suggests that implementation science, community engagement, behavioral science, data science, early detection, and molecular discovery are not parallel activities. They are increasingly interdependent parts of the same scientific enterprise.
Dr. Winn also sees Fox Chase’s next era as inherently collaborative. He speaks about Philadelphia with the language of momentum, borrowing from the city’s cultural history to describe what he hopes can become a regional ecosystem where Temple Health’s Fox Chase Cancer Center works with other cancer centers and advocacy groups to help make the Commonwealth a national force in cancer research, data science, implementation science, early detection, and therapeutic innovation.
His national perspective matters. Dr. Winn has led a major cancer center through transformation, built research programs, advanced clinical trial enrollment, and served in leadership roles across organizations that shape cancer policy and research priorities. Yet his leadership style is deliberately team centered.
“This is not a single person show,” he said. “It’s a we.”
That “we” includes basic scientists, clinicians, population health researchers, implementation scientists, data experts, community leaders, patients, families, philanthropic partners, and public institutions. It also includes the next generation of investigators and physicians, who Dr. Winn encourages to hold on to hope as something active, disciplined, and real.
Hope, in his telling, is not sentiment. It is what allows people to pursue difficult science, enter communities where trust must be earned, and keep working when progress is incremental. It is also what has transformed fields such as lung cancer, where outcomes have improved over the course of his career because scientists, clinicians, patients, and communities refused to accept the limits of what was possible.
At Fox Chase, Dr. Winn sees that same possibility.
The next era, as he frames it, will be built on the center’s extraordinary history, strengthened by Fox Chase Cancer Center’s reach, and driven by a larger ambition: to make discoveries that do not simply advance the field, but reach the people and communities who need them most.
For Dr. Winn, that is the measure of impact. And for Fox Chase, it is a chance to take an already exceptional foundation and ask what more cancer science can become.
Become Part of Tomorrow’s Cancer Care Today
As one of the four original cancer centers to receive comprehensive designation from the National Cancer Institute, Fox Chase Cancer Center has been at the forefront of cancer research for more than 100 years. With a singular focus on cancer, we combine discovery science with state-of-the-art clinical care and population health.
Interested in joining our world-class research team to advance the fight against cancer?
